The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 21)
Improved Biomarkers and Clinical Outcome Measures, 2018
Cognitive-driven Activities of Daily Living Impairment as a Predictor for Parkinson's Disease Dementia
Mild cognitive impairment in Parkinson's disease (PD-MCI) is the highest risk factor for Parkinson's disease dementia (PDD). The core feature for differentiating PDD from PD-MCI is the loss of the ability to perform activities of daily living (ADL). First signs of ADL impairment can be observed in a subgroup of patients with PD-MCI, suggesting that mild ADL impairment in PD-MCI mi...
Researchers: Inga Liepelt-Scarfone, PhD
Research Grant, 2017
The US Food and Drug (FDA) requires acceptable outcome measures to approve a cognitive-enhancing medication for the treatment of mild cognitive impairment (MCI) in Parkinson's disease (PD). The FDA has indicated that the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) is an acceptable combined cognitive-functional outcome for use in clinical trials; however, the CDR-SOB has ...
Researchers: Daniel Weintraub, MD
Improved Biomarkers and Clinical Outcome Measures, 2015
Validation of a Performance-based Assessment of Functional Ability Related to Cognition in Parkinson's Disease
There is a pressing need for new treatments to address cognitive impairment in Parkinson's disease, yet there is no consensus on how to best evaluate their effectiveness. Treatment trials to date mainly use cognitive testing but improvement on such tests has questionable clinical or practical benefits. Functional assessments, which evaluate the ability to perfor...
Research Grant, 2014
Parkinson's disease (PD) dementia is often preceded by a phase of mild cognitive impairment (PD-MCI), for which diagnostic criteria have been recently proposed. However, there remains much that is unknown regarding what causes PD-MCI and PD dementia, why patients exhibit different profiles of cognitive symptoms or functional impairment, which patients are most likely to convert...
Researchers: Jennifer G. Goldman, MD, MS
Access to Data and Biospecimens, 2014
Early detection of neurodegenerative diseases can lead to more effective therapeutic intervention. DiamiR proposes a diagnostic approach based on analysis of microRNAs in plasma. microRNAs are a class of RNA molecules that, due to their small size, can cross the blood-brain barrier and appear in the bloodstream. In several studies microRNA biomarker signatures di...
Researchers: Samuil Umansky, MD, PhD, DrSci